

# Resource Summary Report

Generated by [NIF](#) on Apr 9, 2025

## Polysolver

RRID:SCR\_022278

Type: Tool

### Proper Citation

Polysolver (RRID:SCR\_022278)

### Resource Information

**URL:** <https://software.broadinstitute.org/cancer/cga/polysolver>

**Proper Citation:** Polysolver (RRID:SCR\_022278)

**Description:** Software tool for HLA typing based on whole exome sequencing data and infers alleles for three major MHC class I genes. Enables accurate inference of germline alleles of class I HLA-A, B and C genes and subsequent detection of mutations in these genes using inferred alleles as reference.

**Synonyms:** POLYmorphic loci reSOLVER, POLYSOLVER

**Resource Type:** data analysis software, software resource, software application, data processing software

**Defining Citation:** [PMID:26372948](#)

**Keywords:** HLA typing, whole exome sequencing data, accurate inference of germline alleles, high precision HLA-typing, alleles of class I HLA-A, B and C genes, detection of mutations, inferred alleles

**Funding:** Blavatnik Family Foundation ;  
NHLBI 1R01HL103532;  
NCI 1R01CA155010;  
AACR

**Availability:** Free, Available for download, Freely available

**Resource Name:** Polysolver

**Resource ID:** SCR\_022278

**Record Creation Time:** 20220512T050141+0000

**Record Last Update:** 20250409T061755+0000

---

## Ratings and Alerts

No rating or validation information has been found for Polysolver.

No alerts have been found for Polysolver.

---

## Data and Source Information

**Source:** [SciCrunch Registry](#)

---

## Usage and Citation Metrics

We found 29 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [NIF](#).

Kayhanian H, et al. (2024) Homopolymer switches mediate adaptive mutability in mismatch repair-deficient colorectal cancer. *Nature genetics*, 56(7), 1420.

Zhang H, et al. (2024) Genomic profiling and associated B cell lineages delineate the efficacy of neoadjuvant anti-PD-1-based therapy in oesophageal squamous cell carcinoma. *EBioMedicine*, 100, 104971.

Sun Y, et al. (2024) Integrated multi-omics profiling to dissect the spatiotemporal evolution of metastatic hepatocellular carcinoma. *Cancer cell*, 42(1), 135.

Lee Y, et al. (2023) Characterization of the genomic alterations in poorly differentiated thyroid cancer. *Scientific reports*, 13(1), 19154.

Filip I, et al. (2023) Pervasiveness of HLA allele-specific expression loss across tumor types. *Genome medicine*, 15(1), 8.

Thummalapalli R, et al. (2023) Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non-Small Cell Lung Cancer. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 29(21), 4408.

Wang S, et al. (2023) SpecHLA enables full-resolution HLA typing from sequencing data. *Cell reports methods*, 3(9), 100589.

Yin J, et al. (2023) Neoadjuvant adebrelimab in locally advanced resectable esophageal squamous cell carcinoma: a phase 1b trial. *Nature medicine*, 29(8), 2068.

Spain L, et al. (2023) Late-Stage Metastatic Melanoma Emerges through a Diversity of Evolutionary Pathways. *Cancer discovery*, 13(6), 1364.

Semaan A, et al. (2023) Integrated Molecular Characterization of Intraductal Papillary Mucinous Neoplasms: An NCI Cancer Moonshot Precancer Atlas Pilot Project. *Cancer research communications*, 3(10), 2062.

Zhang X, et al. (2022) Single-cell sequencing reveals CD133+CD44--originating evolution and novel stemness related variants in human colorectal cancer. *EBioMedicine*, 82, 104125.

Vázquez-García I, et al. (2022) Ovarian cancer mutational processes drive site-specific immune evasion. *Nature*, 612(7941), 778.

Sammut SJ, et al. (2022) Multi-omic machine learning predictor of breast cancer therapy response. *Nature*, 601(7894), 623.

Gatenbee CD, et al. (2022) Immunosuppressive niche engineering at the onset of human colorectal cancer. *Nature communications*, 13(1), 1798.

Nguyen PHD, et al. (2021) Intratumoural immune heterogeneity as a hallmark of tumour evolution and progression in hepatocellular carcinoma. *Nature communications*, 12(1), 227.

Claeys A, et al. (2021) Low immunogenicity of common cancer hot spot mutations resulting in false immunogenic selection signals. *PLoS genetics*, 17(2), e1009368.

Au L, et al. (2021) Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma. *Cancer cell*, 39(11), 1497.

Aine M, et al. (2021) Molecular analyses of triple-negative breast cancer in the young and elderly. *Breast cancer research : BCR*, 23(1), 20.

Fangazio M, et al. (2021) Genetic mechanisms of HLA-I loss and immune escape in diffuse large B cell lymphoma. *Proceedings of the National Academy of Sciences of the United States of America*, 118(22).

Ding Z, et al. (2021) Personalized neoantigen pulsed dendritic cell vaccine for advanced lung cancer. *Signal transduction and targeted therapy*, 6(1), 26.